文献速递肿瘤 PET/CT

基线18F-氟胆碱PET/CT呈光子缺失的前列腺癌肝转移治疗后肝脏生理性摄取恢复正常作为应答标志

Normalization of Liver Physiological Uptake as a Response Marker to Treatment in Prostate Cancer Liver Metastases Appearing as Photopenic on Baseline 18F-Fluorocholine PET/CT.
PubMed 文献 · Clin Nucl Med · 2022-09-30

一例54岁经活检证实肝转移的前列腺癌患者,化疗前基线18F-氟胆碱(FCH)PET/CT显示多发低密度肝病灶无FCH摄取及2处阳性骨转移;6周期多西他赛化疗后FCH PET/CT显示已清除肝转移区域生理性摄取接近恢复正常,经前列腺特异性抗原下降及骨转移完全代谢应答证实。本例展示了一种新的应答模式,即应答性肝转移从光子缺失逆转为正常摄取。

要点

  • 基线FCH PET/CT肝转移呈光子缺失,化疗后该区域生理性摄取接近恢复正常。
  • 前列腺特异性抗原下降及骨转移完全代谢应答证实了治疗反应。
  • 提出肝转移从光子缺失逆转为正常摄取这一新应答模式。

核心结论

  • 本例展示了一种新的应答模式,即应答性肝转移从光子缺失逆转为正常FCH摄取。

研究设计与样本

  • 一例54岁经活检证实肝转移的前列腺癌患者,化疗前基线18F-氟胆碱(FCH)PET/CT及6周期多西他赛化疗后FCH PET/CT的病例报告。

主要发现

  • 基线FCH PET/CT显示多发低密度肝病灶无FCH摄取及2处阳性骨转移。
  • 6周期多西他赛化疗后FCH PET/CT显示已清除肝转移区域生理性摄取接近恢复正常。
  • 前列腺特异性抗原下降及骨转移完全代谢应答证实了治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In a 54-year-old patient referred for 18F-fluorocholine (FCH) baseline PET/CT before chemotherapy for biopsy-proven liver metastases, FCH PET/CT demonstrated multiple hypodense hepatic lesions with no FCH uptake and 2 positive bone metastases. FCH PET/CT performed after 6 cycles of docetaxel demonstrated a near normalization of the physiological uptake in the area of the sterilized liver metastases, which was confirmed by a drop in prostate-specific antigen and a complete metabolic response in the bone metastases. The present case demonstrates a new pattern of response defined by a reverse phenomenon from photopenic to normal uptake in responding liver metastases.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Faudemer J, Meriaux E, Tillou X, et al. Normalization of Liver Physiological Uptake as a Response Marker to Treatment in Prostate Cancer Liver Metastases Appearing as Photopenic on Baseline 18F-Fluorocholine PET/CT. Clin Nucl Med. 2022. PMID: 36607367. doi:10.1097/RLU.0000000000004420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。